GenSight Biologics S.A. (EPA:SIGHT)
0.0870
+0.0020 (2.35%)
At close: Mar 13, 2026
GenSight Biologics Employees
GenSight Biologics had 13 employees as of June 30, 2025. The number of employees decreased by 3 or -18.75% since the number was reported on December 31, 2024.
Employees
13
Change
-3
Growth
-18.75%
Revenue / Employee
€72,692
Profits / Employee
€1,163,077
Market Cap
19.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 13 | -3 | -18.75% | 13 | 0 |
| Dec 31, 2024 | 16 | 0 | - | 16 | 0 |
| Dec 31, 2023 | 16 | -29 | -64.44% | 16 | 0 |
| Dec 31, 2022 | 45 | 7 | 18.42% | 45 | 0 |
| Dec 31, 2021 | 38 | 13 | 52.00% | 38 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| genOway Société anonyme | 148 |
| Fermentalg | 63 |
| Aelis Farma | 24 |
| Plant Advanced Technologies | 16 |
| Oncodesign Precision Medicine Société anonyme | 14 |
| Advicenne | 13 |
| TME Pharma | 12 |
| THX Pharma Société Anonyme | 10 |
GenSight Biologics News
- 5 days ago - GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study - Business Wire
- 24 days ago - GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments - Business Wire
- 4 weeks ago - The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study - Business Wire
- 6 weeks ago - GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026 - Business Wire
- 2 months ago - GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates - Business Wire
- 2 months ago - GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel - Business Wire
- 2 months ago - GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France - Business Wire
- 3 months ago - GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France - Business Wire